Is it acceptable to receive a Prolia (denosumab) injection 2.5 weeks later than scheduled? | Rounds Is it acceptable to receive a Prolia (denosumab) injection 2.5 weeks later than scheduled? | Rounds
Loading...

Is it acceptable to receive a Prolia (denosumab) injection 2.5 weeks later than scheduled?

Medical Advisory Board
All articles are reviewed for accuracy by our Medical Advisory Board.

Educational purpose only · Not a substitute for professional judgment or the full text of guidelines and labels.

Article Review Status
Submitted
Under Review
Approved

Last updated: July 14, 2026 · View editorial policy

Prolia (Denosumab) Injection Delay Management

A Prolia (denosumab) dose that is given 2.5 weeks (about 17–18 days) later than scheduled is acceptable when the injection is administered as soon as the patient is available. [1] Subsequent Prolia injections should be scheduled every 6 months from the date of the last injection. [1]

Missed-Dose Timing Guidance

If a dose of Prolia is missed, the injection should be administered as soon as the patient is available. [1] After a missed dose is given, injections should be scheduled every 6 months from the date of the last injection. [1]

Thresholds for Avoiding Excess Delay

Denosumab injections should not be delayed more than 7 months after the previous dose. [2] In population data, delaying subsequent denosumab doses by more than 16 weeks was associated with an increased risk of vertebral fracture compared with on-time dosing. [3]

Practical Scheduling After a 2.5-Week Late Dose

The next injection should be scheduled for 6 months from the actual administration date of the late dose. [1]

When Additional Risk-Mitigation Might Be Considered

If denosumab administration cannot be maintained within 7 months of the prior dose, temporary transition to an oral bisphosphonate (such as weekly alendronate) should be considered. [2]

Key Safety Considerations

Delays and discontinuation can increase bone turnover and vertebral fracture risk, with fractures reported as early as about 7 months after the last denosumab injection. [2]

Evidence Supporting This Timing Approach

Denosumab prescribing information provides direct missed-dose instructions that align with “as soon as patient is available” and rescheduling the next dose 6 months from the last injection. [1] Population data identify increased vertebral fracture risk with delays beyond 16 weeks, which is much longer than a 2.5-week delay. [3]

Adherence to the Dosing Interval

Maintaining timely denosumab dosing is required to prevent rebound-associated increases in bone resorption and vertebral fracture risk. [2] Next injections should follow the 6-month cadence anchored to the date of the last injection. [1]

Related Questions